ReviewHematology/oncology clinics of North America2010
Hematopoietic stem cell transplantation for MDS.
Review in Hematology/oncology clinics of North America, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06923488 (Phase I/II Study of Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory), which is not on this map. Cited by 20 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Phase I/II Study of Leflunomide in Combination With Decitabine for Treatment of Relapsed or Refractory (R/R) Myelodysplastic Syndromes (MDS)
Who cites it
20 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Burden of myelodysplastic syndromes: a systematic literature review of economic burden.The European journal of health economics : HEPAC : health economics in prevention and care · 2025Pooled it
- Trial
- Potential diagnostic, prognostic, and therapeutic implications of ferroptosis in myelodysplastic syndromes.Discover oncology · 2026Review
- Comparison of clinical outcomes between early and delayed allogeneic hematopoietic stem cell transplantation for severe aplastic anemia: a single-center retrospective study.Annals of hematology · 2026Article
- Article
- Psychometric properties and meaningful change thresholds for the QOL-E instrument in patients with myelodysplastic neoplasms.Frontiers in oncology · 2025Article
- Glutathione promotes the synergistic effects of venetoclax and azacytidine against myelodysplastic syndrome‑refractory anemia by regulating the cell cycle.Experimental and therapeutic medicine · 2023Article
- Generalist in allogeneic hematopoietic stem cell transplantation for MDS or AML: Epigenetic therapy.Frontiers in immunology · 2022Review
- OMIP-080: 29-Color flow cytometry panel for comprehensive evaluation of NK and T cells reconstitution after hematopoietic stem cells transplantation.Cytometry. Part A : the journal of the International Society for Analytical Cytology · 2022Article
- A Personalized Prediction Model for Outcomes after Allogeneic Hematopoietic Cell Transplant in Patients with Myelodysplastic Syndromes.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2020Article
- Reduced-intensity fludarabine/melphalan confers similar survival to busulfan/fludarabine myeloablative regimens for patients with acute myeloid leukemia and myelodysplasia.Leukemia & lymphoma · 2020Article
- Immunotherapy in Myeloproliferative Diseases.Cells · 2020Review
- An in vitro assessment for evaluating the efficiency of β-d-mannuronic acid (M2000) in myelodysplastic syndrome.Journal of cellular physiology · 2019Article
- Chimeric antigen T cell receptor treatment in hematological malignancies.Blood research · 2019Article
- Impact of T-cell depletion on outcome of patients undergoing allogeneic hematopoietic cell transplantation for myelodysplastic syndrome.Bone marrow transplantation · 2018Article
- Scoring System Prognostic of Outcome in Patients Undergoing Allogeneic Hematopoietic Cell Transplantation for Myelodysplastic Syndrome.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2016Article
- Allogeneic hematopoietic cell transplantation for MDS: for whom, when and how?Blood reviews · 2012Review
- Myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation: diagnostic and therapeutic challenges.American journal of hematology · 2012Article
- Pretransplantation therapy with azacitidine vs induction chemotherapy and posttransplantation outcome in patients with MDS.Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation · 2012Article
- Current status of allogeneic hematopoietic cell transplantation for MDS.Current pharmaceutical design · 2012Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Hematopoietic stem cell transplantation (HSCT) offers potentially curative therapy for patients with myelodysplastic syndromes (MDS). However, as the majority of patients with MDS are in the seventh or eighth decade of life, conventional transplant regimens have been used only infrequently, and only with the development of reduced-intensity conditioning has transplantation been applied more broadly to older patients. Dependent upon disease status at the time of transplantation, 30% to 70% of patients can be expected to be cured of their disease and survive long term. However, posttransplant relapse and graft-versus-host disease (GVHD) remain problems and further investigations are needed.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.